Linezolid for the treatment of serious gram-positive infections

McAuley L
Record ID 32001000090
English, French
Authors' objectives:

To summarise the available evidence on the use of linezolid (Zyvox(R)) in the treatment of serious gram-positive infections.

Authors' recommendations: The rate of resistance of the three most common gram-positive pathogens has increased dramatically in the last decade. In the United States vancomycin resistance in enterococci has risen from less than 1% to 18% exhibiting resistance. The strength of linezolid comes from its demonstrated ability to handle serious infection for which current therapy is limited (i.e. vancomycin resistant enterococci and methicilin-resistant staphlococcus). However, its efficacy for the treatment of many less serious gram-positive bacterial infections is equal to that of comparator antibiotics. Linezolid will provide a valuable option for the treatment of patients with serious gram-positive infections resistant to standard therapy. Experience with linezolid is limited to 28-day therapy, mainly in the form of industry run trials and cases of compassionate use. There is much momentum in the development of therapies for serious gram-positive infections. Only time will tell where linezolid will fit among the new and emerging options.
Authors' methods: Overview
Project Status: Completed
Year Published: 2001
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
MeSH Terms
  • Gram-Positive Bacterial Infections
Organisation Name: Canadian Coordinating Office for Health Technology Assessment
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
Contact Email:
Copyright: Canadian Coordinating Office for Health Technology Assessment
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.